0 Bewertungen0% fanden dieses Dokument nützlich (0 Abstimmungen)
340 Ansichten4 Seiten
Nucleon is a small biotech company that needs to carefully select partnership and project opportunities for continued growth. The document recommends that Nucleon focus its product pipeline on projects that fulfill unmet medical needs, allow for proprietary positions, have predictable models, add technological value, and can be scaled up. Nucleon should evolve into an R&D company with pilot manufacturing capabilities. Revenue from licensing its CRP-1 molecule could fund further development of other molecules and mammalian cell technologies.
Nucleon is a small biotech company that needs to carefully select partnership and project opportunities for continued growth. The document recommends that Nucleon focus its product pipeline on projects that fulfill unmet medical needs, allow for proprietary positions, have predictable models, add technological value, and can be scaled up. Nucleon should evolve into an R&D company with pilot manufacturing capabilities. Revenue from licensing its CRP-1 molecule could fund further development of other molecules and mammalian cell technologies.
Nucleon is a small biotech company that needs to carefully select partnership and project opportunities for continued growth. The document recommends that Nucleon focus its product pipeline on projects that fulfill unmet medical needs, allow for proprietary positions, have predictable models, add technological value, and can be scaled up. Nucleon should evolve into an R&D company with pilot manufacturing capabilities. Revenue from licensing its CRP-1 molecule could fund further development of other molecules and mammalian cell technologies.
Developing new partnerships is an important strategy for the continued growth and success of Nucleon Increasing the availability of resources, expanding capabilities and strengthening internal research and development. Due to its small size, Nucleon needs to carefully select its portfolio of projects. Suggestions
Nucleon to base its product pipeline on the following criteria: There is an unmet medical need There is a chance to achieve a dominant proprietary positions There are predictable preclinical models The used technology adds value The cell lines can be scaled-up Nucleon should evolve into an R&D boutique with pilot scale manufacturing capabilities. The revenue in form of royalties from the diverse therapeutic application of the CRP-1 molecule would accelerate the in-house development of the other molecules and of the mammalian cells technology. Focus on developing a mammalian cells technology, which makes developing biologics faster, easier, safer and more cost-effective than the conventional bacterial cells method. Nucleon will have to continuously improve its innovative technology; therefore it is necessary to build a pilot plant designed to manufacture products using mammalian cells fermentation; This will give it a competitive advantage on the other companies using the traditional technology.